Summary of Malignant Melanoma: Diagnosis, Staging, and Treatment
Malignant Melanoma: Diagnosis, Staging, Treatment for Students
Introduction
Metastatic melanoma is melanoma that has spread beyond the primary skin site to regional nodes or distant organs. Systemic care includes cytotoxic chemotherapy, immune-based therapies, and molecularly targeted agents. This material summarizes systemic treatment approaches, evidence for key regimens, surveillance considerations after systemic therapy, and practical points for patient selection and toxicity management.
Definition: "Metastatic melanoma" refers to melanoma that has spread to lymph nodes or distant organs and typically requires systemic therapies rather than curative local surgery alone.
Overview of systemic treatment categories
- Cytotoxic chemotherapy: traditional agents such as dacarbazine (DTIC), temozolomide, cisplatin, vinblastine, paclitaxel, carboplatin.
- Biochemotherapy: combinations of cytotoxic drugs with biologic agents (e.g., IL-2, IFN-α) to try to improve response rates.
- Immune checkpoint blockade and immune modulation: e.g., ipilimumab (anti-CTLA-4), cytokine therapies (high-dose IL-2), tumor vaccines, adoptive cell therapies.
- Molecularly targeted therapy: targeted inhibitors for tumors with driver mutations, notably BRAF V600E inhibitors such as PLX4032 (vemurafenib).
Cytotoxic chemotherapy: agents and evidence
Key agents
- Dacarbazine (DTIC): long-standing community standard; response rates ~10–20%.
- Temozolomide: oral alkylator with similar efficacy to DTIC; crosses the blood–brain barrier (useful for brain metastases).
- Combination regimens: CVD (cisplatin, vinblastine, dacarbazine) and Dartmouth (dacarbazine, carmustine, cisplatin, tamoxifen) showed higher response rates in early reports but did not consistently improve survival in later trials.
- Paclitaxel ± carboplatin: can yield short-lived responses (median benefit 2–7 months).
Practical points
- Expect modest response rates and short median response durations (typically a few months).
- Use temozolomide when brain penetration is desirable.
Definition: "Response rate" measures the percentage of patients with tumor size reduction of a predefined amount; "median survival" is the time at which 50% of patients remain alive.
Biochemotherapy
Rationale
Combine chemotherapy and immunologically active agents (IL-2, IFN-α) to increase tumor kill and potentially augment immune responses.
Evidence and outcomes
- Early phase II trials reported overall response rates from about 27% to 64% and complete responses in some cohorts.
- Randomized trials (e.g., intergroup E3695) showed modest increases in response rate and progression-free survival but no consistent improvement in overall survival compared with chemotherapy alone.
- Biochemotherapy is substantially more toxic than chemotherapy alone; attempts to reduce toxicity (e.g., subcutaneous IL-2) did not show clear survival benefit.
- Meta-analysis: improved response rates but no survival benefit overall.
Practical guidance
- Consider biochemotherapy only in clinical-trial settings or carefully selected patients who can tolerate high toxicity and when potential short-term tumor shrinkage is clinically meaningful.
Immune therapies
High-dose interleukin-2 (IL-2)
- Approved by FDA for metastatic melanoma (1998).
- Overall objective response rate ~17%; complete responses in ~6% of highly selected patients with long durability (median response duration >59 months in responders).
- Toxicity is significant and limits use to centers experienced in managing IL-2 side effects.
Immune checkpoint blockade: Ipilimumab
- Mechanism: monoclonal antibody against CTLA-4, which normally down-regulates T-cell activation; blockade augments antitumor immunity.
- Clinical trial data: randomized multicenter trial showed improved overall survival, improved progression-free survival, and higher best overall response rate compared with vaccine alone.
- Toxicity: immune-related adverse events occurred in about 60% of patient
Sign up for the full summaryAlready have an account? Sign in
Metastatic Melanoma Systemic Care
Klíčová slova: Melanoma: Skin Types & Presentation, Melanoma surgical techniques, Melanoma lymph node surgery, Nevi, Melanoma: General Overview & Classification, Cutaneous Melanoma Diagnosis & Pathology, Melanoma Staging, Nodal & Metastasis Evaluation, Lymph Nodes, Medical and Radiation Therapy: Melanoma Local Treatment, Medical and Radiation Therapy: Metastatic Melanoma Systemic Care
Klíčové pojmy: Dacarbazine and temozolomide produce modest response rates (~10–20%) and short median response durations (~3–4 months)., Temozolomide crosses the blood–brain barrier and is preferred when brain metastases are a concern., Biochemotherapy increases response rates but has not shown consistent overall survival benefit and is substantially more toxic., High-dose IL-2 yields durable complete responses in ~6% of highly selected patients but has high toxicity and requires specialized centers., Ipilimumab (anti-CTLA-4) improved overall survival in randomized trials but causes immune-related adverse events in ~60% of patients., Test all metastatic melanomas for BRAF V600E; vemurafenib (PLX4032) produces high response rates in mutation-positive tumors., Surveillance after systemic therapy requires dermatologic exams, patient education for self-detection, and targeted imaging or labs when indicated., Prefer enrollment in clinical trials for vaccine or novel immune strategies due to limited proven benefit of current vaccines., Select systemic approach based on mutation status, disease distribution, performance status, and prior therapies., Manage immune toxicities early with standard measures (e.g., corticosteroids) and involve experienced multidisciplinary teams.